Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease
- PMID: 21284856
- PMCID: PMC3042008
- DOI: 10.1186/1755-1536-4-4
Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease
Abstract
Background: Connective tissue growth factor (CTGF) is widely thought to promote the development of fibrosis in collaboration with transforming growth factor (TGF)-β; however, most of the evidence for its involvement comes from correlative and culture-based studies. In this study, the importance of CTGF in tissue fibrosis was directly examined in three murine models of fibrotic disease: a novel model of multiorgan fibrosis induced by repeated intraperitoneal injections of CTGF and TGF-β2; the unilateral ureteral obstruction (UUO) renal fibrosis model; and an intratracheal bleomycin instillation model of pulmonary fibrosis.
Results: Intraperitoneal coadministration of CTGF and TGF-β2 elicited a profound fibrotic response that was inhibited by the human anti-CTGF antibody FG-3019, as indicated by the ability of FG-3019 to ameliorate the histologic signs of fibrosis and reduce the otherwise increased hydroxyproline:proline (Hyp:Pro) ratios by 25% in kidney (P < 0.05), 30% in liver (P < 0.01) and 63% in lung (P < 0.05). Moreover, administration of either cytokine alone failed to elicit a fibrotic response, thus demonstrating that CTGF is both necessary and sufficient to initiate fibrosis in the presence of TGF-β and vice versa. In keeping with this requirement for CTGF function in fibrosis, FG-3019 also reduced the renal Hyp:Pro response up to 20% after UUO (P < 0.05). In bleomycin-injured animals, a similar trend towards a FG-3019 treatment effect was observed (38% reduction in total lung Hyp, P = 0.056). Thus, FG-3019 antibody treatment consistently reduced excessive collagen deposition and the pathologic severity of fibrosis in all models.
Conclusion: Cooperative interactions between CTGF and TGF-β signaling are required to elicit overt tissue fibrosis. This interdependence and the observed anti-fibrotic effects of FG-3019 indicate that anti-CTGF therapy may provide therapeutic benefit in different forms of fibroproliferative disease.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3042008/bin/1755-1536-4-4-1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3042008/bin/1755-1536-4-4-2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3042008/bin/1755-1536-4-4-3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3042008/bin/1755-1536-4-4-4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3042008/bin/1755-1536-4-4-5.gif)
Similar articles
-
Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β.Matrix Biol. 2019 Sep;82:20-37. doi: 10.1016/j.matbio.2019.01.002. Epub 2019 Feb 1. Matrix Biol. 2019. PMID: 30716392
-
The Sirt1 activator, SRT1720, attenuates renal fibrosis by inhibiting CTGF and oxidative stress.Int J Mol Med. 2017 May;39(5):1317-1324. doi: 10.3892/ijmm.2017.2931. Epub 2017 Mar 22. Int J Mol Med. 2017. PMID: 28339034
-
Profibrotic mediators in tendon disease: a systematic review.Arthritis Res Ther. 2016 Nov 18;18(1):269. doi: 10.1186/s13075-016-1165-0. Arthritis Res Ther. 2016. PMID: 27863509 Free PMC article. Review.
-
Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis.Kidney Int. 2000 Oct;58(4):1389-99. doi: 10.1046/j.1523-1755.2000.00301.x. Kidney Int. 2000. PMID: 11012874 Review.
-
Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model.J Cell Physiol. 1999 Oct;181(1):153-9. doi: 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K. J Cell Physiol. 1999. PMID: 10457363
Cited by
-
Effect of antibody-mediated connective tissue growth factor neutralization on lung edema in ventilator-induced lung injury in rats.Mol Med. 2024 May 22;30(1):68. doi: 10.1186/s10020-024-00829-4. Mol Med. 2024. PMID: 38778274 Free PMC article.
-
Connective Tissue Growth Factor: Regulation, Diseases, and Drug Discovery.Int J Mol Sci. 2024 Apr 25;25(9):4692. doi: 10.3390/ijms25094692. Int J Mol Sci. 2024. PMID: 38731911 Free PMC article. Review.
-
Ginkgo biloba extract ameliorates skin fibrosis in a bleomycin-induced mouse model of systemic sclerosis.Anim Cells Syst (Seoul). 2024 Apr 18;28(1):152-160. doi: 10.1080/19768354.2024.2337761. eCollection 2024. Anim Cells Syst (Seoul). 2024. PMID: 38645438 Free PMC article.
-
Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets.J Clin Med. 2024 Mar 25;13(7):1881. doi: 10.3390/jcm13071881. J Clin Med. 2024. PMID: 38610646 Free PMC article. Review.
-
A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials.BMC Pulm Med. 2024 Jan 27;24(1):58. doi: 10.1186/s12890-024-02861-w. BMC Pulm Med. 2024. PMID: 38281037 Free PMC article.
References
-
- Kochanek KD, Murphy SL, Anderson RN, Scott C. Deaths: final data for 2002. Natl Vital Stat Rep. 2004;53:1–115. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous